- Home
- SNY
SNY
Sanofi ADS
as 03-25-2025 2:33pm EST
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
| Founded: | 1994 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 144.8B | IPO Year: | N/A |
| Target Price: | $62.50 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | Dividend Payout Frequency: | Annual | |
| EPS: | 4.60 | EPS Growth: | 2.94 |
| 52 Week Low/High: | $45.22 - $60.12 | Next Earning Date: | 04-24-2025 |
| Revenue: | $45,849,466,833 | Revenue Growth: | 7.73% |
| Revenue Growth (this year): | 6.91% | Revenue Growth (next year): | 6.60% |
Latest Sanofi ADS News
SNY Breaking Stock News: Dive into SNY Ticker-Specific Updates for Smart Investing
Zacks
a day ago
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
GlobeNewswire
a day ago
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
GlobeNewswire
2 days ago
Press Release: Availability of the Q1 2025 Aide mémoire
Zacks
5 days ago
Pharma Stock Roundup: PFE's Final Haleon Stake Sale, AZN, SNY M&A Deals
The Fly
5 days ago
FedEx downgraded, Adobe upgraded: Wall Street's top analyst calls
Bloomberg
5 days ago
Banks Launch €7.45 Billion Debt Sale for Sanofi Unit Buyout
Pharmaceutical Technology
6 days ago
Sanofi outlays $1.9bn to purchase Dren Bio’s bispecific antibody
Zacks
6 days ago
Sanofi Inks $1.9B Deal With Dren Bio to Buy Autoimmune Disease Drug
Compare SNY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNY Sanofi ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.